Tonix Pharmaceuticals Says It Is Developing A Vaccine Candidate Called TNX-801 As WHO Declared MPOX A Public Health Emergency Of International Concern On Aug. 14
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals is developing a vaccine candidate, TNX-801, in response to the WHO's declaration of MPOX as a public health emergency. The vaccine has shown promising results in non-human primate studies against the Clade 1 monkeypox virus.
August 23, 2024 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals is developing TNX-801, a vaccine candidate for MPOX, with promising results in non-human primate studies. This development follows the WHO's emergency declaration.
The development of TNX-801 by Tonix Pharmaceuticals is a significant step in addressing the MPOX public health emergency. The successful non-human primate studies suggest potential efficacy, which could positively impact TNXP's stock as investors anticipate further progress and potential market approval.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90